Ability of orally administered IFN-α-containing transgenic potato extracts to inhibit Listeria monocytogenes infection

Journal of Interferon and Cytokine Research

Volumn 25, Issue 8, 2005, Pages 459-466

  Ohya, Kenji ^a,b   Matsumura, Takeshi ^c,d   Itchoda, Noriko ^d   Ohashi, Kazuhiko ^a   Onuma, Misao ^a   Sugimoto, Chihiro ^e  

^a HOKKAIDO UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Hokkaido Green Bio Institute   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^e OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; IMMUNOTHERAPY; INFECTION PREVENTION; LISTERIA MONOCYTOGENES; LISTERIOSIS; MOUSE; NONHUMAN; POTATO; PRIORITY JOURNAL; TRANSGENIC PLANT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; FEMALE; HUMANS; INTERFERON-ALPHA; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; PLANTS, GENETICALLY MODIFIED; SOLANUM TUBEROSUM;

ANIMALIA; LISTERIA MONOCYTOGENES; SOLANUM TUBEROSUM;

EID: 23944473204     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.459     Document Type: Article

References (59)

1. Tyring SK. Introduction to clinical use of interferons. In: Tyring SK, ed. Interferon: Principles and Medical Applications. Galveston: The University of Texas at Galveston; 1992:399-408.
2. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 1994;91:1198-1205.
3. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J. Leukocyte Biol. 2002;71:565-581.
4. Bosio E, Beilharz MW, Watson MW, Lawson CM. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo. J. Interferon Cytokine Res. 1999;19:869-876.
5. Lawson CM, Beilharz MW. Low-dose oral use of interferon inhibits virally induced myocarditis. J. Interferon Cytokine Res. 1999; 19:863-867.
6. Beilharz MW, McDonald W, Watson MW, Heng J, McGeachie J, Lawson CM. Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res. 1997;17:625-630.
7. Baqar S, Pacheco ND, Rollwagen FM. Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines. Antimicrob. Agents Chemother. 1993;37:2688-2692.
8. Buret A, Olson ME, Gall DG, Hardin JA. Effects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits. Infect. Immun. 1998;66: 4917-4923.
9. Matsuzawa K, Yoo YC, Fukushima A, Yoshimatsu K, Arikawa J, Azuma I. Protective effect of mucosal administration of recombinant human macrophage colony-stimulating factor (rhM-CSF) on mucosal infection of Sendai virus in mice. Vaccine 1997;15:85-89.
10. Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 1998;28:2780-2790.
11. Slavin AJ, Maron R, Weiner HL. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int. Immunol. 2001;13:825-833.
12. Rollwagen FM, Baqar S. Oral cytokine administration. Immunol. Today 1996;17:548-550.
13. Cummins JM, Beilharz MW, Krakowka S. Oral use of interferon. J. Interferon Cytokine Res. 1999;19:853-857.
14. Goldman AS. Modulation of the gastrointestinal tract of infants by human milk. Interfaces and interactions. An evolutionary perspective. J. Nutr. 2000;130:426S-431S.
15. Satoh Y, Kasama K, Kuwabara M, et al. Suppression of late asthmatic response by low-dose oral administration of IFN-β in the guinea pig model of asthma. J. Interferon Cytokine Res. 1999; 19:887-894.
16. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjögren's syndrome with low-dose natural human IFN-α administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J. Interferon Cytokine Res. 1999; 19:943-951.
17. Cummins JM, Guthrie D, Hutcheson DP, Krakowka S, Rosenquist BD. Natural human IFN-α administered orally as a treatment of bovine respiratory disease complex. J. Interferon Cytokine Res. 1999;19:907-910.
18. Cummins MJ, Pruitt B. Low-dose oral use of human IFN-α in cancer patients. J. Interferon Cytokine Res. 1999;19:937-941.
19. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49:585-593.
20. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 1996;17:369-372.
21. Bogdan C. The function of type I interferons in antimicrobial immunity. Curr. Opin. Immunol. 2000;12:419-424.
22. Biron CA. Interferons alpha and beta as immune regulators-a new look. Immunity 2001;14:661-664.
23. Vazquez-Boland JA, Kuhn M, Berche P, et al. Listeria pathogenesis and molecular virulence determinants. Clin. Microbiol. Rev. 2001;14:584-640.
24. North RJ, Dunn PL, Conlan JW. Murine listeriosis as a model of antimicrobial defense. Immunol. Rev. 1997;158:27-36.
25. Unanue ER. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol. Rev. 1997;158:11-25.
26. Nakane A, Minagawa T, Yasuda I. Induction of alpha/beta interferon and gamma interferon in mice infected with Listeria monocytogenes during pregnancy. Infect. Immun. 1985;50:877-880.
27. Fujiki T, Tanaka A. Antibacterial activity of recombinant murine beta interferon. Infect. Immun. 1988;56:548-551.
28. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. 2001;6:219-226.
29. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. Plant-based production of biopharmaceuticals. Curr. Opin. Plant Biol. 2004;7:152-158.
30. Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol. Med. 2002;8:324-329.
31. Walmsley AM, Arntzen CJ. Plant cell factories and mucosal vaccines. Curr. Opin. Biotechnol. 2003;14:145-150.
32. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. 1998;4: 607-609.
33. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 2000;182: 302-305.
34. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl. Acad. Sci. USA 2001;98:11539-11544.
35. Ohya K, Matsumura T, Ohashi K, Onuma M, Sugimoto C. Expression of two subtypes of human IFN-α in transgenic potato plants. J. Interferon Cytokine Res. 2001;21:595-602.
36. Fukuda S, Ando S, Sanou O, et al. Simultaneous production of natural human tumor necrosis factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulated by HVJ. Lymphokine Res. 1988; 7:175-185.
37. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989;7:145-173.
38. Decker T, Stockinger S, Karaghiosoff M, Muller M, Kovarik P. IFNs and Stats in innate immunity to microorganisms. J. Clin. Invest. 2002;109:1271-1277.
39. Foster GR, Rodrigues O, Ghouze F, et al. Different relative activities of human cell-derived IFN-α subtypes: IFN-α8 has very high antiviral potency. J. Interferon Cytokine Res. 1996;16:1027-1033.
40. Week PK, Apperson S, May L, Stebbing N. Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J. Gen. Virol. 1981;57: 233-237.
41. Brunda MJ, Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res. 1984;44:597-601.
42. Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med. 2001;7:356-360.
43. Cummins JM, Krakowka SG, Thompson CG. Systemic effects of interferons after oral administration in animals and humans. Am. J. Vet. Res. 2005;66:164-176.
44. Buchmeier NA, Schreiber RD. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc. Natl. Acad. Sci. USA 1985;82:7404-7408.
45. Samuel CE. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001;14:778-809.
46. Mattner J, Schindler H, Diefenbach A, Rollinghoff M, Gresser I, Bogdan C. Regulation of type 2 nitric oxide synthase by type I interferons in macrophages infected with Leishmania major. Eur. J. Immunol. 2000;30:2257-2267.
47. Diefenbach A, Schindler H, Donhauser N, et al. Type I interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite. Immunity 1998;8: 77-87.
48. Mattner J, Wandersee-Steinhauser A, Pahl A, et al. Protection against progressive leishmaniasis by IFN-beta. J. Immunol. 2004; 172:7574-7582.
49. Schafer TW, Lieberman M, Cohen M, Came PE. Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 1972;176:1326-1327.
50. Nakajima A, Sokawa Y. Induction of blood 2′,5′-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-τ. J. Interferon Cytokine Res. 2002;22:397-402.
51. Takayama S, Iwaki K, Nishida Y, et al. Effects of oral administration of IFN-α on antibody production in mice with induced tolerance. J. Interferon Cytokine Res. 1999;19:895-900.
52. Manca C, Tsenova L, Bergtold A, et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc. Natl. Acad. Sci. USA 2001;98: 5752-5757.
53. O'Connell RM, Saha SK, Vaidya SA, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 2004;200:437-445.
54. Straub RH, Westermann J, Scholmerich J, Falk W. Dialogue between the CNS and the immune system in lymphoid organs. Immunol. Today 1998;19:409-413.
55. Downing JE, Miyan JA. Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol. Today 2000;21:281-289.
56. Soos JM, Stuve O, Youssef S, et al. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J. Immunol. 2002; 169:2231-2235.
57. Streatfield SJ, Jilka JM, Hood EE, et al. Plant-based vaccines: unique advantages. Vaccine 2001;19:2742-2748.
58. Sanders PR, Winter JA, Barnason AR, Rogers SG, Fraley RT. Comparison of cauliflower mosaic virus 35S and nopaline synthase promoters in transgenic plants. Nucleic Acids Res. 1987;15:1543-1558.
59. Aarestrup FM, Wegener HC. The effects of antibiotic usage in food animals on the development of antimicrobial resistance of importance for humans in Campylobacter and Escherichia coli. Microbes Infect. 1999;1:639-644.